Paper Details

  1. Home
  2. Paper Details

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.

Author: BowlerM, Hilton-JonesD, LochmuellerH, LongmanC, PettyR, RobertsM, RogersM, TurnerC, WilcoxD

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Modafinil, a psychostimulant drug, has been found to be effective in treating excessive daytime sleepiness (EDS) in myotonic dystrophy type 1 (DM1) patients. While recent European Medicines Agency (EMA) reviews have restricted its use to narcolepsy due to potential serious side effects, clinical experience suggests that modafinil is effective in carefully selected DM1 patients with a very low incidence of serious adverse events.
Paper Details　
Original Abstract of the Article :
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is extremely common in myotonic dystrophy type 1 (DM1). In a significant minority it has a profound disabling effect on employment, social functioning and activities of daily living. Limited published st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.nmd.2012.02.005

データ提供：米国国立医学図書館（NLM）

Modafinil: A Potential Oasis in the Desert of Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1), a genetic disorder affecting muscle function, can lead to a range of challenges, including excessive daytime sleepiness (EDS). This research explores the potential of modafinil, a medication commonly used to treat narcolepsy, in managing EDS in DM1 patients. The authors sought to understand the patients' perspectives on the use of modafinil for this condition.

Modafinil: A Potential Solution for EDS in DM1

The study found that modafinil was effective in reducing EDS in a significant proportion of DM1 patients, providing a potential oasis in the desert of fatigue and sleepiness. It's like finding a refreshing spring in the middle of a long and arduous journey. The authors also emphasized the importance of careful patient selection and monitoring for potential side effects.

Finding a Path to Improved Quality of Life

This research highlights the potential of modafinil for improving the quality of life for DM1 patients struggling with EDS. It underscores the importance of careful patient selection and monitoring to ensure safe and effective treatment. As we navigate the desert of chronic illness, finding ways to manage debilitating symptoms is crucial for promoting well-being and improving overall quality of life.

Dr. Camel's Conclusion

This study provides valuable insights into the potential of modafinil for managing EDS in DM1 patients. It underscores the importance of individualized care and highlights the need for further research to understand the long-term impact of this medication on DM1 patients. While the desert of chronic illness can be challenging, research and innovative treatments continue to offer hope for a brighter future.
Date :
  1. Date Completed 2012-11-13
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22425060

DOI: Digital Object Identifier

10.1016/j.nmd.2012.02.005

Related Literature

Article Analysis
・Side Effects of modafinil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.